{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:38:59Z","timestamp":1793392739795,"version":"4.5.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Multiple sclerosis (MS) treatment has radically improved over the last years; however, MS symptom management is still challenging. The novel Spasticity-Plus syndrome was conceptualized to frame several spasticity-related symptoms that can be addressed together with broad-spectrum medication, such as certain cannabinoid-based drugs. The aim of this project was to gain insight into Spanish neurologists' clinical experience on MS spasticity and associated symptoms, and to assess the acknowledgment and applicability of the Spasticity-Plus syndrome concept in patients with MS.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Ten online meetings were conducted using the Workmat<jats:sup>\u00ae<\/jats:sup> methodology to allow structured discussions. Fifty-five Spanish neurologists, experts in MS management, completed and discussed a set of predefined exercises comprising MS symptom assessment and its management in clinical practice, MS symptoms clustering in clinical practice, and their perception of the Spasticity-Plus syndrome concept. This document presents the quantitative and qualitative results of these discussions.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The specialists considered that polytherapy is a common concern in MS and that simplifying the management of MS spasticity and associated manifestations could be useful. They generally agreed that MS spasticity should be diagnosed before moderate or severe forms appear. According to the neurologists' clinical experience, symptoms commonly associated with MS spasticity included spasms\/cramps (100% of the specialists), pain (85%), bladder dysfunction (62%), bowel dysfunction (42%), sleep disorders (42%), and sexual dysfunction (40%). The multiple correspondence analysis revealed two main symptom clusters: spasticity-spasms\/cramps-pain, and ataxia-instability-vertigo. Twelve out of 16 symptoms (75%) were scored &amp;gt;7 in a 0\u201310 QoL impact scale by the specialists, representing a moderate\u2013high impact. The MS specialists considered that pain, spasticity, spasms\/cramps, bladder dysfunction, and depression should be a treatment priority given their frequency and chance of therapeutic success. The neurologists agreed on the usefulness of the new Spasticity-Plus syndrome concept to manage spasticity and associated symptoms together, and their experience with treatments targeting the cannabinoid system was satisfactory.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> The applicability of the new concept of Spasticity-Plus in MS clinical practice seems possible and may lead to an integrated management of several MS symptoms, thus reducing the treatment burden of disease symptoms.<\/jats:p>","DOI":"10.3389\/fneur.2021.722801","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T16:43:38Z","timestamp":1632761018000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Integrated Management of Multiple Sclerosis Spasticity and Associated Symptoms Using the Spasticity-Plus Syndrome Concept: Results of a Structured Specialists' Discussion Using the Workmat\u00ae Methodology"],"prefix":"10.3389","volume":"12","author":[{"given":"Oscar","family":"Fernandez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucienne","family":"Costa-Frossard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Mart\u00ednez-Gin\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paloma","family":"Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Mar\u00eda","family":"Prieto-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Llu\u00eds","family":"Rami\u00f3-Torrent\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S1474-4422(18)30443-5","article-title":"Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 GBD 2016 Multiple Sclerosis Collaborators*","volume":"18","author":"Wallin","year":"2019","journal-title":"Artic Lancet Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1177\/1352458520968811","article-title":"Atlas of MS 2020: Informing global policy change","volume":"26","author":"Coetzee","year":"2020","journal-title":"Mult Scler J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.33588\/rn.6901.2018477","article-title":"Epidemiology of multiple sclerosis in Spain","volume":"69","author":"P\u00e9rez-Carmona","year":"2019","journal-title":"Rev Neurol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","article-title":"Multiple sclerosis","volume":"4","author":"Filippi","year":"2018","journal-title":"Nat Rev Dis Prim."},{"key":"B6","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/joim.12204","article-title":"A changing treatment landscape for multiple sclerosis: challenges and opportunities","volume":"275","author":"Piehl","year":"2014","journal-title":"J Intern Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S1474-4422(20)30063-6","article-title":"Rethinking multiple sclerosis treatment strategies","volume":"19","author":"Filippi","year":"2020","journal-title":"Lancet Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41582-018-0082-z","article-title":"Treatment of multiple sclerosis \u2014 success from bench to bedside","volume":"15","author":"Tintore","year":"2019","journal-title":"Nat Rev Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1136\/jnnp-2016-315238","article-title":"Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study","volume":"88","author":"Lunde","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B10","doi-asserted-by":"publisher","first-page":"146","DOI":"10.7224\/1537-2073.2012-053","article-title":"Natural history of multiple sclerosis symptoms","volume":"15","author":"Kister","year":"2013","journal-title":"Int J MS Care."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2020.00152","article-title":"The broad concept of \u201cspasticity-plus syndrome\u201d in multiple sclerosis: a possible new concept in the management of multiple sclerosis symptoms","volume":"11","author":"Fern\u00e1ndez","year":"2020","journal-title":"Front Neurol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/ncpuro1298","article-title":"Sexual dysfunction in patients with multiple sclerosis: a multidisciplinary approach to evaluation and management","volume":"6","author":"Fletcher","year":"2009","journal-title":"Nat Clin Pract Urol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/14740338.2020.1720646","article-title":"Polypharmacy among patients with multiple sclerosis: a qualitative systematic review","volume":"19","author":"Frahm","year":"2020","journal-title":"Expert Opin Drug Saf."},{"key":"B14","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jpsychores.2014.02.013","article-title":"Polypharmacy in multiple sclerosis: Relationship with fatigue, perceived cognition, and objective cognitive performance","volume":"76","author":"Thelen","year":"2014","journal-title":"J Psychosom Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1586\/erp.11.6","article-title":"Retrospective observational study of the management of multiple sclerosis patients with resistant spasticity in Spain: the \u201c5E\u201d study","volume":"11","author":"Arroyo","year":"2011","journal-title":"Expert Rev Pharmacoeconomics Outcomes Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1191\/1352458504ms1085oa","article-title":"Prevalence and treatment of spasticity reported by multiple sclerosis patients","volume":"10","author":"Rizzo","year":"2004","journal-title":"Mult Scler."},{"key":"B17","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3109\/00207454.2012.762364","article-title":"Spasticity in multiple sclerosis: results of a patient survey","volume":"123","author":"Oreja-Guevara","year":"2013","journal-title":"Int J Neurosci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1126\/science.1115740","article-title":"Identification and Functional Characterization of Brainstem Cannabinoid CB2 Receptors","volume":"310","author":"Van Sickle","year":"2005","journal-title":"Science (80-)."},{"key":"B19","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1191\/1352458504ms1082oa","article-title":"Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients","volume":"10","author":"Wade","year":"2004","journal-title":"Mult Scler J."},{"key":"B20","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1179\/016164109X12590518685660","article-title":"A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis","volume":"32","author":"Collin","year":"2010","journal-title":"Neurol Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/j.1468-1331.2010.03328.x","article-title":"A randomized, double-blind, placebo-controlled, parallel- group, enriched-design study of nabiximols* (Sativex \u00ae), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis","volume":"18","author":"Novotna","year":"2011","journal-title":"Eur J Neurol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/00207454.2018.1481066","article-title":"Sativex \u00ae as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomized clinical trial","volume":"129","author":"Markov\u00e0","year":"2019","journal-title":"Int J Neurosci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1007\/s10072-020-04413-6","article-title":"Effects of THC\/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study","volume":"41","author":"Patti","year":"2020","journal-title":"Neurol Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.aprim.2015.11.004","article-title":"Percepci\u00f3n de los m\u00e9dicos sobre los factores que influyen en la elecci\u00f3n de un dicumar\u00ednico o de un nuevo anticoagulante oral en pacientes con fibrilaci\u00f3n auricular no valvular","volume":"48","author":"Anguita-S\u00e1nchez","year":"2016","journal-title":"Atenci\u00f3n Primaria."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fpsyt.2018.00054","article-title":"1st international experts' meeting on agitation: Conclusions regarding the current and ideal management paradigm of agitation","volume":"9","author":"Mart\u00ednez-Raga","year":"2018","journal-title":"Front Psychiatry."},{"key":"B26","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1080\/01621459.1963.10500845","article-title":"Hierarchical grouping to optimize an objective function","volume":"58","author":"Ward","year":"1963","journal-title":"J Am Stat Assoc."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1474-4422(10)70249-0","article-title":"Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions","volume":"9","author":"Thompson","year":"2010","journal-title":"Lancet Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.msard.2015.10.007","article-title":"Spasticity in multiple sclerosis: associations with impairments and overall quality of life","volume":"5","author":"Milinis","year":"2016","journal-title":"Mult Scler Relat Disord."},{"key":"B29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.33588\/rn.4506.2007239","article-title":"Guide to the comprehensive treatment of spasticity","volume":"45","author":"Vivancos-Matellano","year":"2007","journal-title":"Rev Neurol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/ane.12202","article-title":"Spasticity in patients with multiple sclerosis - clinical characteristics, treatment and quality of life","volume":"129","author":"Flachenecker","year":"2014","journal-title":"Acta Neurol Scand."},{"key":"B31","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1191\/135245801680209330","article-title":"Reduced quality of life among multiple sclerosis patients with sexual disturbance and bladder dysfunction","volume":"7","author":"Nortvedt","year":"2001","journal-title":"Mult Scler."},{"key":"B32","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1191\/1352458503ms904oa","article-title":"Fatigue associated with multiple sclerosis: diagnosis, impact and management","volume":"9","author":"Bakshi","year":"2003","journal-title":"Mult Scler."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1177\/1352458508096684","article-title":"Cognitive impairment in multiple sclerosis","volume":"15","author":"Patti","year":"2009","journal-title":"Mult Scler."},{"key":"B34","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/JNN.0b013e3181e26c5f","article-title":"Symptom cluster and quality of life: preliminary evidence in multiple sclerosis","volume":"42","author":"Motl","year":"2010","journal-title":"J Neurosci Nurs."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.jpainsymman.2009.11.312","article-title":"Symptom cluster and quality of life in multiple sclerosis","volume":"39","author":"Motl","year":"2010","journal-title":"J Pain Symptom Manage."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1177\/1352458518799580","article-title":"Symptomatology and symptomatic treatment in multiple sclerosis: results from a nationwide MS registry","volume":"25","author":"Rommer","year":"2019","journal-title":"Mult Scler J."},{"key":"B37","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jpainsymman.2008.08.004","article-title":"Symptom cluster as a predictor of physical activity in multiple sclerosis: preliminary evidence","volume":"38","author":"Motl","year":"2009","journal-title":"J Pain Symptom Manage."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/203183","article-title":"Symptoms and association with health outcomes in relapsing-remitting multiple sclerosis: results of a US patient survey","volume":"2014","author":"Williams","year":"2014","journal-title":"Mult Scler Int."},{"key":"B39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1037\/rep0000027","article-title":"Pain affects depression through anxiety, fatigue, and sleep in multiple sclerosis","volume":"60","author":"Amtmann","year":"2015","journal-title":"Rehabil Psychol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1212\/CON.0000000000000325","article-title":"Symptom management and lifestyle modifications in multiple sclerosis","volume":"22","author":"Coyle","year":"2016","journal-title":"Contin Lifelong Learn Neurol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.brs.2019.09.012","article-title":"Transcranial direct current stimulation (tDCS) for the treatment of a Multiple Sclerosis symptom cluster","volume":"13","author":"Workman","year":"2020","journal-title":"Brain Stimul."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.722801\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T16:43:40Z","timestamp":1632761020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.722801\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,27]]},"references-count":41,"alternative-id":["10.3389\/fneur.2021.722801"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.722801","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,27]]},"article-number":"722801"}}